






































RASGRF1 is a guanine nucleotide-releasing factor for 
RAS that is activated by calmodulin-mediated Ca
2+ 
influx [1] as well as G-protein coupled receptors [2, 3]. 
RASGRF1 serves as an in vivo activator for H-RAS and 
members of the R-RAS and RAC subfamilies [4]. 
Guanine nucleotide-releasing factors interact with the 
inactive RAS bound to GDP and catalyze the exchange 
of GDP for GTP, thereby activating RAS. In contrast 
with other RAS-GTP exchange factors, RASGRF1 is 
expressed mainly in pancreatic β-cells where it 
regulates  β-cell mass and in specific brain regions 
including the hippocampus and hypothalamus, thus 
linking RASGRF1-dependent RAS activation to 
glucose homeostasis and neuronal function [5, 6].  
 
 





































Previous reports have demonstrated that RasGrf1-
defcient mice display defects in learning and memory, 
although the explanation for these impairments 
remains controversial [5, 7]. Similar to RasGrf1 null 
mice generated in a different strain [8], our knockout 
mice display reduced body size. Additionally, we 
observed that RasGrf1-deficiency causes hypo-
insulinemia due to a reduction in β-cell proliferation 
and β-cell mass [6]. However, perhaps owing to the 
fact that the size of these animals is reduced, insulin 
levels are sufficient to compensate under normal 
conditions and thus, diabetes does not develop in this 
model. Therefore, RASGRF1-mediated signaling is 





































control  mice.  Protection  against  oxidative  stress  was  similarly  preserved  in  old  RasGrf1






deficienct  mice  display  delayed  aging.  Our  observations  link  Ras  signaling  to  lifespan  and  suggest  that  RasGrf1  is  an
evolutionary conserved gene which could be targeted for the development of therapies to delay age‐related processes.  
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aging in yeast. Mutations that decrease the activity of 
the  RAS/Cyr1/PKA pathway extend longevity and 
increase stress resistance in yeast by activating 
transcription factors Msn2/Msn4 and the mitochondrial 
superoxide dismutase [9]. It has also been reported that 
Ras genes are a major homeostatic device in the 
regulation of the lifespan of S. cerevisiae [10]. The 
longevity-modulating function of IGF-I in C. elegans 
displays a signal bifurcation involving the Ras ortholog 
Let-60, consistent with a role for RAS signaling 
downstream of IGF-IR. Attenuated insulin/IGF-I 
signaling (IIS) is hypothesized to mediate some of the 
anti-aging effects of calorie restriction in mice [11]. 
Importantly, mice heterozygous for the IGF-IR live 
longer and are resistant to oxidative stress [12]. 
Moreover, calorie restriction has been suggested to 
down-regulate pathways including m-TOR, AKT and 
RAS [13].  
 
Several studies with cultures of mammalian cells have 
suggested that RAS might be involved in aging and 
age-related processes such as apoptosis. Apoptosis in 
neurons, T cells, and human epithelial cells is 
mediated by the activation of RAS [14] [15, 16]. On 
the contrary, inhibition of RAS rescues PC12 cells 
from apoptosis [17]. Moreover, inhibition of RAS in 
these cells increases resistance to oxidative stress [18, 
19]. 
 
However, few studies have addressed the potential role 
of RAS signaling in regulating lifespan in mammals 
[20]. Based on the previous data from our laboratory 
[6] as well as others [8], we hypothesized that 
RasGrf1-deficient mice could have increased 
longevity. We measured plasma IGF-I levels as it 
related to RAS and aging. We studied the expression 
of cytochrome c oxidase to determine whether 
oxidative stress is altered in RasGrf1-deficient mice. 
Finally, to test the idea that RasGrf1  deficiency 
promotes beneficial metabolic changes, we compared 
the metabolomic profile of our RasGrf1-deficient mice 
with calorie restricted controls. 
  
Our studies reveal that loss of RasGrf1 (RasGrf1-KO) 
expands not only average but also maximal lifespan in 
mice. These mice display lower plasma levels of IGF-1, 
lower oxidative stress and a metabolic profile which 
resembles that observed in calorie-restricted wild-type 
animals. Thus, RasGrf1 deficiency in mice promotes 
longevity consistent with the lifespan extension 
associated with loss of IGF-I signalling molecules from 













































Survival curves revealed a marked increase (20%) in the 
average lifespan of RasGrf1
-/- male mice (mean values 
WT: 100.5±4.2 weeks and RasGrf1
-/-: 120.7±4.7 weeks; 
median WT: 104 weeks; RasGrf1
-/-: 124 weeks) (p= 
6x10
-5, Logrank test). The effects of RasGrf1 deficiency  
were also evident on maximal lifespan; WT mice lived 
up to 146.7 weeks whereas RasGrf1 mutants lived as 





WT  n  =  47;  RasGrf1
‐/‐  n  =  45.  Report  the  Kaplan  –  Meyer
representation  of  the  two  groups  (p<0.05).  (B)  Percentage  of
























**to maximal lifespan supports a critical role for RasGrf1 
in longevity. In fact, 19,2% of RasGrf1
-/- mice lived 
longer than the oldest WT (Figure 1B). The lifespan of 
our WT mice is within the range of variation reported 
for C57B1, 129 and hybrids [21-27]. 
 
One plausible explanation for these longevity promoting 
effects could be the role of RASGRF1 in RAS 
activation and hence, in cancer development. To test 
this possibility, we identified those animals that 
developed tumors and generated a tumor-free survival 
curve. Consistent with the curve generated for the total 
population, RasGrf1
-/- without tumors displayed a 20% 
increase in average lifespan as compared with tumor-
free control mice (mean values WT: 99±4.5 weeks and 
RasGrf1
-/-: 119±4.9; median WT: 102 weeks; RasGrf1
-/-
: 121 weeks) (p= 0.0003, Logrank test) (Figure 1B). 
Thus, the role of RAS in cancer is not the reason for the 
longer longevity of RasGrf1
-/- mice. No obvious 
pathological differences were observed at death 
between WT and RasGrf1
-/- mice. The substantial 
increase in average and maximal lifespan suggests 
RasGrf1 as a novel age-associated gene. 
 
RasGrf1
-/- Mice Show Better Motor Coordination 
than Controls  
 
Maintaining good motor coordination in old age is 
important to ensure that living longer is accompanied 
by an adequate quality of life. Young RasGrf1
-/- mice 
displayed superior motor coordination in the 
tightrope test as compared to WT controls (Figure 
2A). Whereas motor coordination of WT mice 
declined significantly with age, old RasGrf1
-/- 
maintained a level of motor coordination that was 
similar to young animals (Figure 2A). Thus, our 
analysis suggests that RasGrf1
-/- mice not only live 
longer but they are less prone to frailty. 
 
Expression of 16S rRNA is higher in RasGrf1
-/- mice 
than in control mice 
 
We examined the expression levels of 16S rRNA, 
which decreases significantly with age [28, 29] and 
oxidative stress [30]. 16S RNA levels were much higher 
in liver of RasGrf1
-/- than WT of the same age (Figure 
2B). This result is consistent with the increased lifespan 
observed in RasGrf1

















































-/- Mice Display Less Oxidative Stress 
 
To analyze the contribution of the free radicals to the 
increased lifespan associated with RasGrf1 deficiency, 
we assessed three of the critical parameters of oxidative 
stress: glutathione, protein oxidation, and malondial-
dehyde (MDA) which is a measurement of lipid 
peroxidation. Oxidative stress diminishes the levels of 






Figure  2.  Increased  Neuromuscular  Coordination
Coincided With Biomarkers of Aging in RasGrf1
‐/‐ Mice.
(A)  Neuromuscular  coordination  was  quantified  as  the
percentage of male mice that successfully passed the tightrope
test. Numbers within the bars indicate animals that passed the
test  divided  by  the  total  number  of  animals  which  were
subjected to the test. Young animals were 4‐6 months old, and
old  animals  were  20‐22  months  old.  Significance  is  shown  as
*p<0.05;  **p<0.01  vs.  WT.  (B)  Liver  extracts  from  male  mice
were  used  to  assess  16S  rRNA  expression  in  4‐6  months  old




























































protein antioxidant in cells, to form the disulphide 
bond-dimer (GSSG). The GSSG/GSH ratio was 
significantly lower in brain and liver of RasGrf1
-/- mice 
as compared with controls (Figure 3A,B upper panels), 
indicating that RasGrf1
-/-mice are subjected to less 
oxidative stress. Additionally, lipid peroxide levels were 
significantly lower in RasGrf1
-/- mice (Figure 3A,B 
lower panels). Since aging is characterized by the 
accumulation of oxidized proteins due to increased 
protein damage and/or decreased elimination, we 
evaluated this parameter in liver of young and old 
animals. The overall oxidized protein levels in liver of 
RasGrf1
-/- were significantly lower than in age-matched 
WT mice (Figure 3C). These results support the idea 
that loss of RasGrf1 protects against oxidative damage 
and hence, contributes to a younger phenotype. We next 
examined a possible molecular basis of these findings. 
Low levels of cytochrome c oxidase, the terminal 
enzyme in the mitochondrial electron transport chain, 
increase the production of reactive oxygen species 
(ROS) [31]. Interestingly, the expression levels of 
cytochrome c oxidase were significantly higher in liver 
of RasGrf1
-/- mice (Figure 3D). Thus, disruption of the 
RAS signaling via deletion of RasGrf1 up-regulates the 
expression of cytochrome c oxidase, providing at least 




Higher Glycogen Hepatic Content In RasGrf1
-/- Mice 
 
Aging is characterized by a diminished response to 
stress [32]. Maintenance of glycogen storage is 
important in the stress response [33]. We found that 
hepatic glycogen in WT mice was virtually absent after 
24 hours of fasting whereas RasGrf1
-/- mice maintained 
significant glycogen levels (Figure 4A). Our findings 
reveal a glycogen-sparing effect mediated by loss of a 
specific gene. Maintenance of relatively high levels of 
glycogen in fasting would be expected to convey a 
metabolic advantage in response to stress during aging. 
 
Increased Expression of SIRT1 in RasGrf1
-/- mice 
Sirtuins have appear to play a role in determining 
longevity [34], but their importance in mammalian 
lifespan is not clear (Herranz & Serrano 2010). We 
observed that the levels of SIRT1 are increased in the 
liver and heart of RasGrf1
-/- mice (Figure 4B). High 
sirtuin might explain the glycogen sparing effect that we 
have shown above (see discussion). 
 
IGF-1 Levels Are Lower in RasGrf1
-/- Mice 
 
Long-lived animals display low IGF-1 levels [35-37]. 
We observed a significant decrease of IGF-1 in 
RasGrf1





(n=7)  than  in  RasGrf1
‐/‐  male  mice  (n=8).  Malondialdehyde
(MDA) levels were significantly lower in brain of RasGrf1
‐/‐ mice
(n=8)  than  in  that  of  WT  (n=7).  MDA  was  measured  by  the
formation  of  the  aduct  malondialdehyde‐thiobarbituric  acid
(MDA‐TBA)  (*p<0.05).  (B)  Oxidised  glutathione  and
malondialdehyde  levels  were  significantly  lower  in  liver  of
RasGrf1
‐/‐  male  mice.  n  for  WT  =  7  and  for  RasGrf1
‐/‐  =  8
(*p<0.05) (4‐6 months old). (C) Oxidised proteins in young (4‐6






























































Therefore, this could explain, at least in part, the 
increased longevity of RasGrf1
-/- mice. Consistent with 
the low IGF-1 levels, somatic growth was also reduced 
in RasGrf1















































Metabolomics Reveal that the Metabolic Profile of 
RasGrf1
-/- Mice Resembles Calorie Restricted Mice 
 
To gain further insight into the mechanisms that 
promote increased average and maximal lifespan 
RasGrf1
-/- mice, we performed metabolomic studies in 
which we compared RasGrf1
-/- animals with WT 
animals, and calorie-restricted WT animals. Figure 5A 







the  complete  absence  in  WT  animals  (4‐6  months  old).  PAS
staining was quantified using color deconvolution with ImageJ
software (Broken Symmetry Software). Values represent relative
staining  of  three  different  sections  (*p=0.01  determined  by  a
paired T‐test). (B) Sirtuin mRNA expression in liver and heart of
RasGrf1
‐/‐  male  mice  is  significantly  higher  than  in  WT  mice
(*p=0.033;  #p=0.035).  Wild‐type  n  =  4,  RasGrf1









a  metabolic  shift  of  RasGrf1
‐/‐  fed  male  mice  towards  caloric
restricted WT (4‐6 months old). Multivariate analysis (PLS – DA)
of  NMR  spectra  of  blood  plasma  showing  global  metabolic
profiles of WT, RasGrf1
‐/‐, and calorie restricted WT mice. The
graph  represents  the  scores  plot  of  the  PLS‐DA  model  for
discrimination between WT and RasGrf1
‐/‐. The graph also shows
the  metabolic  profile  of  WT  animals  on  caloric  restriction
projected over the PLS‐DA latent space. Each symbol represents
an  animal.  (B)  Glucose  up‐take  in  vivo  by  heart  of  WT  and
RasGrf1
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the three groups represented in the plot indicates that 
the metabolic profile exhibited by RasGrf1
-/- animals is 
shifted towards that of the CR animals. The multivariate 
analysis reveals a set of metabolites with significant 
variations between WT and RasGrf1
-/- mice (Figure S1). 
Most of these metabolic differences also occur in CR 
such as an increase in the levels of polyunsaturated fatty 
acids (PUFA; 14%, p=0.002), and decrease in glucose 


































Glucose Uptake In Vivo Is Maintained in Aged 
RasGrf1
-/- Mice But Not in Control Mice 
 
We used positron emission tomography (PET) to 
analyze in vivo glucose uptake in young and old animals 
since reduced glucose uptake is associated with aging 
[38]. Glucose uptake by heart of control animals was 
significantly lowered with age. Surprisingly, this loss of 
glucose consumption did not occur with aging in 
RasGrf1
-/- animals (Figure 5B). Thus, although the 
critical parameter of glucose incorporation in cardiac 





Interest in genetic components that modulate longevity 
in mammals has grown in recent years [39, 40]. 
According to the National Institute on Aging (NIA), the 
genetically heterogeneous mouse model was deemed to 
be the most suitable for longevity studies [41], even if 
this increases the genetic variability of each mouse and 
decreases the power of attaining statistical significance 
[39]. We have recently reported that over-expressing 
two (p53/p16) [42] or three (p53/p16/telomerase) [43] 
genes results in significant increases in average lifespan 
but without increasing maximal lifespan. Here we report 
a significant increase in maximal lifespan by the 
deletion of RasGrf1 in inbred mice with a 
heterogeneous background. Increasing maximal lifespan 
is important because it indicates a fundamental change 
in the aging process. Improvements in lifestyle 
conditions usually result in increases to average but not 
maximal lifespan [32]. Extrapolating to humans, curing 
all diseases would result in an increase of less than 20% 
in average lifespan without changing maximal lifespan 
[32]. 
 
Motor coordination is an important determinant of 
frailty, a major geriatric syndrome [44, 45]. Ladiges et 
al. have emphasized the importance of finding genetic 
modifications that improve patho-physiological 
functions associated with aging, such as motor 
coordination [39]. We have found that motor 
coordination is improved in the RasGrf1 deficient mice 
(Figure 2A), thus indicating that these animals not only 
live longer but are less prone to frailty. 
 
Based on genomic scanning with methylation sensitive 
enzymes, RasGrf1 was postulated as a paternally 
imprinted gene in the mouse [46]. This was confirmed 
by the subsequent generation of RasGrf1-deficient 
mice; studies of heterozygous animals demonstrated 
that RasGrf1 is an imprinted gene regulated by the male 
and modulates postnatal growth because it functions 
after, rather than before, birth [8]. The imprinted nature 
of RasGrf1 was further validated by the characterization 
of two nonsense mutations that when paternally 
transmitted caused reduced body weight during 
postnatal development [47]. A more recent study with 
bi-maternal mice revealed that the sperm genome has a 
detrimental effect on longevity, most likely due to the 
repression of RasGrf1 in this model [48]. In contrast to 
other imprinted genes that are implicated in fetal 
growth, RasGrf1 regulates postnatal growth. RASGRF1 
is expressed after birth in the hypothalamus of wild-type 
mice, but not in the pituitary, where it indirectly 
regulates the synthesis of growth hormone [8]. Many 
genes that modulate longevity directly or indirectly 
Figure 6. Schematic Representation of the Molecular and
Physiological  Characteristics  of  RasGrf1
‐/‐  Animals.
RasGrf1‐/‐ results in an increased longevity which is mediated by
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inherited via the female parent. Similar to other 
paternally expressed genes, RasGrf1 is involved in 
growth stimulation, whereas maternally expressed genes 
are responsible for growth suppression [8, 49]. Hence, 
our results describe a longevity-related gene which is 
solely determined by the male parent. 
 
Circulating IGF-I levels and body size are important 
determinants of lifespan [37]. A previous publication 
reported reduced IGF-I circulating levels and adult body 
size in mice deficient for RasGrf1
-/- [8]. However, this 
model was generated in pure 129 sv genetic background 
which is distinct from our own RasGrf1
-/- mice which 
are genetically heterogeneous mice. Since genetic 
background can exert a profound effect in parameters 
such as metabolism and growth ratio, we measured 
IGF-I circulating levels in our own RasGrf1
-/- model. In 
agreement with the other knockout model, circulating 
IGF-I was reduced by 39% in our RasGrf1
-/- mice 
(Figure 4C). Hence, RasGrf1
-/- mice display both low 
insulin and IGF-I levels that may significantly impact 
systemic IIS. In agreement with low IGF-1 levels, 
RasGrf1
-/- mice display reduced body weight (See 
Figure S3). We previously reported that food intake, 
circulating leptin levels and leptin receptor expression 
in the hypothalamus are very similar between WT and 
RasGrf1
-/- mice [6], suggesting that food intake is not 
the mechanism for the longer lifespan of RasGrf1
-/- 
mice. Therefore, the increase in lifespan observed in 
RasGrf1
-/- mice is most probably due to their lower 
insulin and IGF-1 levels.  
 
Lower serum IGF-I and insulin levels are characteristic 
of animals subjected to caloric restriction and are 
associated with increased SIRT1 expression and 
reduced oxidative stress [50, 51]. In this paper we also 
show higher levels of SIRT1 expression (Figure 4B) 
and reduced oxidative stress (Figure 3) in RasGrf1
-/- 
mice. Metabolomic results also indicate that RasGrf1
-/- 
mice could resemble in some way calorie restricted 
mice, as it is shown in Figure 5. The positive effects of 
CR on lifespan extension may involve the down-
regulation of pathways, including mTOR, AKT, and 
RAS [13]. Our results demonstrate a novel 
physiological function of the RAS modulator 
RASGRF1 in extending both median and maximum 
lifespan. 
 
SIRT1 deacetylates PPARγ and its co-activator PGC1α, 
thereby promoting fat mobilization and increasing 
mitochondrial size and number [52-55]. Activation of 
SIRT1 stimulates hepatic energy expenditure by 
increasing the degradation of fatty acids [56]. 
Conversely, under fasting conditions (e.g. CR), 
glycolytic genes are repressed through a mechanism 
that involves PGC1α and SIRT1 [55]. Therefore, 
increased SIRT1 expression would be expected to 
enhance this repression and promote the accumulation 
of glucose reservoirs in the form of glycogen. Indeed, 
increased hepatic SIRT1 expression correlated with 
enhanced glycogen accumulation in the liver of fasted 
RasGrf1
-/- mice (Figure 4A). Although glycogen storage 
is regulated through a plethora of conditions, the fact 
that RasGrf1
-/- mice exhibit higher liver glycogen levels 
could also be consistent with increased SIRT1 levels 
mediated by FoxO1-dependent transcriptional activity 
[57]. In contrast, hepatic glycogen levels after a 24 hour 
fast were undetectable WT control mice.  
 
Glucose uptake favors a metabolic phenotype that 
protects against age-associated susceptibility to 
ischemic injury [58]. Therefore, preservation of cardiac 
glucose uptake may represent yet another physiological 
advantage for the RasGrf1
-/- extended lifespan. Decline 
in cardiac performance with age is prevented in 
Drosophila by disruption of insulin receptor signaling 
specifically in the heart [59]. Additionally, higher 
plasma concentrations of PUFA detected in RasGrf1
-/- 
are also expected to have beneficial effects for 
cardiovascular disease and lifespan. 
 
The increased longevity of RasGrf1
-/- mice may be 
explained by the low IGF-1 levels [37]. The 
physiological explanation linking these low levels and 
RasGrf1 deficiency at the cellular level is very difficult to 
obtain because RasGrf1
  is only expressed in hippo-
campus, hypothalamic, β-pancreatic and mature 
adipocytes. Adipocytes do not synthesize IGF-I. 
Hypothalamic and β-pancreatic cell do but they cannot be 
obtained in sufficient amounts to perform cell- signaling 
studies. Cells usually used in these kinds of studies, like 
mouse embryonic fibroblasts do not express RasGrf1.  
The involvement of Ras, but not RasGrf1, in longevity 
has been extensively studied by Longo and coworkers 
[20, 60, 61]. These authors have shown in yeast, that 
RAS regulates stress resistance and longevity by 
activating transcription factors Msn2/Msn4 and the 
mitochondrial antioxidant enzyme superoxide dismutase 
(Sod2) [60]. We also observed less oxidative stress in the 
RasGrf1  deficient mice, and we show that the 
mitochondrial antioxidant enzyme which is up-regulated 
is cytochrome c oxidase (Figure 3). Thus, the increased 
longevity and resistance to stress in RasGrf1  deficient 
mice show that the negative influence of the RAS pathway 
may be conserved mechanism from yeast to mammals.  
 
Moreover, based in a genome-wide association study, 
Sebastiani and co-workers found a set of 150 single 
nucleotide polymorphisms (SNPs) that can predict 
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approach for predicting EL provided valuable 
information regarding genes that contribute to EL. 
RasGrf1 was found to be one of such genes. We have 
demonstrated that deficiency in RasGrf1 expands not 
only average but also maximal lifespan, thus revealing 
to be a longevity-conserved gene in rodents and 
humans. Recently, Kawahara and Kono found that bi-
maternal mice (i.e. “mice without a father”) exhibited 
increased longevity and this was attributed it to lack of 
RasGrf1 [48].  
 
In summary, our results demonstrate that RasGrf1
-/- 
display less oxidative stress than control mice and also 
have lower insulin/IGF-1 circulating and higher sirtuin 
expression. Thus, the increase in maximal longevity in 
this model may be explained by the fact that two main 
theories of aging (the free radical and the IGF-I 




MATERIALS AND METHODS 
 
Mice. Male wild-type (WT) and RasGrf1
-/- mice were 
maintained in ventilated cages and survival function 
was estimated from lifespan data. 
 
Handling, supervision and experimentation with mice 
was done in accordance to the Guidelines for Humane 
Endpoints for Animals Used in Biomedical Research. 
Mice were housed at the pathogen-free barrier area of the 
Prince Felipe Research Centre. Moribund criteria was 
established and approved by the Ethical Committee at the 
Prince Felipe Research Centre. These criteria were based 
on the suggested clinical endpoints for aging mice 
according to McGill University’s Ethics Subcommittee 
(www.mcgill.ca/files/researchoffice/Aging-mice-6.doc). 
Briefly, animals were assigned a health score based on 
their general appearance, wounds, prolapses, size and 
location of tumors, etc., as described in Table S1. 
Depending of the score, animals were monitored daily 
when symptoms were minor. In more critical cases (loss 
of vital functions or a score over 18 points) animals 
were immediately euthanized. 
 
RasGrf1
-/- mice were originally generated in 1998 at 
NCI facilities in Frederick (MD). Transfections were 
done in RW-4 cells (derived from 129SvJ mouse strain) 
to obtain the gene deletion. Cells were injected into 
C57BL/6N blastocysts to generate chimera animals that 
were further backcrossed twice with C57Bl/6N mice to 
generate both, wild-type and RasGrf1-/-  mice. No 
further backcrosses were done with C57Bl/6N. 
 
From 1998 to present, the colony has been routinely 
propagated by homozygous matings [6]. However, 
animals for the longevity study were generated by 
crossing heterozygous animals in order to obtain sibling 
controls.  
 
Diet provided was Harlan Teklad Global Maintenance 
2014 (Harlan Italy). Animals used for the longevity 
curve were solely used for this study. Animals were 
allowed to die naturally except when their vital 
constants were compromised and were further 
euthanized.  
 
Food intake. To measure food intake in mice, 5 male 
RasGrf1-/- mice and 5 age-matched (2 months old) 
wild-type mice were weight and kept in separate cages. 
Mice were provided with powder food (2014 Global 
Rodent Maintenance Powder, Harlan Teklad) and intake 
of the diet was measured by successive daily weighings 
of the food container to an accuracy of 0.01 g on a top-
loading electronic balance (Sartorius). Food intake was 
not significative different between these mice [6]; wild-
type 131±6 and RasGrf1
-/- 141±7 mg/g body 
weight/day; p=0.4).  
 
Tightrope test. The tightrope test is a widely used and 
extensively validated behavioural marker of ageing 
[63]. We performed the test with slight variations: mice 
were placed on a bar of circular section (60 cm long and 
1.5 cm diameter) and the test was considered successful 
when a mouse did not fall during a period of 60 s in at 
least one out of five consecutive trials.  
 
Quantitative real-time RT–PCR. Total RNA from 
tissues was extracted with Trizol (Life Technologies). 
Messenger RNA levels were measured by quantitative 
real-time polymerase chain reaction using the Tth DNA 
polymerase kit (Roche Diagnostics-Boehringer 
Mannheim), as described by the manufacturer. Real-
time quantitation of mRNAs for 16S rRNA and situins 
relative to GAPDH mRNA was performed using the 
iCycler (Bio-Rad, Hercules, CA) with SYBR Green I 
detection. Target cDNAs were amplified in separate 
tubes: 10 min at 95°C, then 40 cycles of denaturation 
(95°C for 30 s) and annealing and extension (at 62°C 
for 1 min per cycle). The increase in fluorescence was 
measured during the extension step. The threshold cycle 
(Ct) was determined, and the relative gene expression 
was expressed as fold change = 2
(–ΔΔCt). Specific primers 
used were 16S rRNA, 5´-
GACGAGAAGACCCTATGGAG-3´ and 5´-
AGAAACCGACCTGGATTGC-3´; SIRT-1 5'-
CCAGATCCTCAAGCCATG TT-3' and 5'-
TTGCAGGAATCCAAAGGATC-3' and GAPDH, 5′- 
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GGTCCTCAGTGTAGCCCAAGATG-3′. The error 




Measurement of oxidative stress parameters and IGF-I 
levels. Glutathione ratio (GSSG/GSH*100) was 
determined by high-performance liquid chromatography 
(HPLC) as described [64]. Lipid peroxidation was 
determined as accumulation of MDA, which was 
detected by HPLC as an MDA–thiobarbituric acid 
adduct [65]. Oxidative modification of total proteins 
was assessed by immunoblot detection of protein 
carbonyl groups using the ‘OxyBlot’ protein oxidation 
kit (Intergen) following the manufacturer’s instructions. 
The procedure to quantify total protein carbonyls with 
the OxyBlot kit was densitometry of the oxyblot and of 
the Ponceau staining, followed by finding the ratio 
between the total density in the oxyblot and the total 
density in the Ponceau. Serum levels of IGF-I were 
measured using retro-orbital blood and the Mouse/Rat 
IGF-I kit from Diagnostic Systems Laboratories. 
 
Determination of heart glucose consumption in vivo. 
Mice were deprived of food for 8–14 h before 18F-2-
fluor-2-deoxiglucose (18F-FDG) injection. 18F-FDG 
(5.8–11.1 MBq) was injected  intraperitoneally after 
anesthesia with isoflurane (1.5–2% in  100% oxygen, 
IsoFlo; Abbott Laboratories). PET was started 60 min 
after 18F-FDG injection as described in [66]. 18F-FDG 
was synthesized  as previously described [67]. The 
administered dose (FDG activity) was indeed corrected 
for body weight. We acquired 20-min static images 60 
min after injection of 18FFDG. The biodistribution of 
18F-FDG by the heart was compared between all the 
studied groups. The PET images were obtained with the 
Albira small animal PET (ONCOVISION, GEM-
Imaging). Regions of interest were manually drawn 
over the brain and heart with PMOD software. Tracer 
uptake by heart was quantified as SUV (Standardized 
Uptake Value, Total Sum). 
 
Storage, preparation and 
1H NMR spectroscopic 
analysis of blood serum. Mice blood sera were stored at 
-80C and thawed before use. For NMR analysis, 20 μl 
of serum were mixed with 2 μl of D2O (as a field lock). 
A total of 20 μL of the mixture of each sample was then 
transferred into a 1 mm high quality NMR capillary 
individually. All 
1H NMR spectra were acquired using a 
standard one-dimensional pulse sequence with water 
suppression (Bruker Avance 600 spectrometer operating 
at 600.13 MHz with a 1mm 
1H/
13C/
15N TXI probe). A 
total of 256 FIDs (free induction decay) were collected 
into 64k data points with a spectral width of 14 ppm and 
the recycle delay (RD) of 1 s. Water signal was 
saturated with a weak irradiation during the recycle 
delay. Before Fourier transformation, the free induction 
decay was multiplied by a 0.3 Hz exponential line 
broadening. Spectral chemical shift referencing on the 
Alanine CH3 doublet signal at 1.475 ppm was 
performed in all spectra. Spectral regions between 0.5 
and 4.5 ppm and between 5.5 and 9.5 ppm were binned 
in segments of 0.01 ppm width (6 Hz) for multivariate 
analysis. We normalized the binned data to total 
spectral area. We used available spectral databases and 
2D NMR experiments to aid structural identification of 
relevant metabolites. All spectra were processed using 
MNova (MestreLab, Santiago de Compostela, Spain) 
and transferred to MATLAB® (MathWorks Inc, 2006) 
using in-house scripts for data analysis. Signals 
belonging to selected metabolites (Glucose, signal at 
3.79 ppm and PUFA signal at 2.70 ppm) were integrated 
and quantified using semi-automated in-house MATLAB 
peak-fitting routines. These fitting routine were based on 
Levenburg-Marquard optimization procedures. The target 
function for the optimization included experimental 
spectra measured for standard solutions of selected 
metabolites with complex multiplet patterns and 
theoretically generated Lorentzian-shape signals for those 
metabolites with simpler spectral patterns. One-way-
analysis of variance (ANOVA) was used for the 
determination of statistical significance between group 
means of the corresponding integrals. 
 
Multivariate analysis of NMR spectra. We used 
PLS_Toolbox 5.0 (Eigenvector Research, WA, USA) 
for MATLAB® to build the PLS-DA models. PLS-DA 
is a classification technique that encompasses the 
properties of Partial Least Squares regression with the 
discrimination power of discriminant analysis [68]. The 
main advantage of PLS-DA models is that the main 
sources of variability in the data are modeled by the so-
called latent variables (LVs), and consequently, in their 
associated scores and loadings, allowing the 
visualization and understanding of different patterns and 
relations in the data. Binned spectral regions for blood 
serum from normally fed WT and RasGrf1
-/- mice were 
mean-centered for building a PLS-DA model. The PLS-
DA model discriminating between WT and RasGrf1
-/- 
was cross-validated by the leave-on-out method 
providing a cross-validation RMS of 0.3816 and a cross 
validation classification error of 0.0625. Q residual and 
Hotelling T
2 for 95% interval of confidence were 
0.5047 and 14.28 respectively. Then, we project the 
spectra of blood serum from calorie restricted WT mice 
to this PLS-DA latent space for evaluating metabolic 
proximity between groups.  
 
Glycogen content determination. Livers from 24 hours 
fasted animals were embedded in paraffin and 5μm 
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Gender Animal  ID RasGrf1  D.O.B. D.O.D.  Weeks  alive 
♂  705-2  KO  5/6/2007  8/1/2007  12.428571 
♂  302-2  KO  12/12/2005  10/23/2006  45 
♂  37-1  KO  1/28/2005  7/31/2006  78.428571 
♂  505-3(w)  KO  8/21/2006  2/23/2008  78.714286 
♂  92-1  KO  5/17/2005  12/18/2006  82.857143 
♂  173-1  KO  9/6/2005  6/11/2007  91.857143 
♂  274-1  KO  11/22/2005  9/1/2007  92.571429 
♂   5-5  KO  1/10/2005  11/5/2006  94.857143 
♂  427-2  KO  4/16/2006  3/6/2008  98.571429 
♂  504-2(w)  KO  8/21/2006  7/22/2008  100.14286 
♂  228-1  KO  10/18/2005  9/28/2007  101.42857 
♂  426-1  KO  4/16/2006  3/31/2008  102.14286 
♂  62-2  KO  2/21/2005  2/23/2007  104.57143 
♂  481-2(w)  KO  7/9/2006  8/5/2008  108.28571 
♂  611-2  KO  1/22/2007  2/19/2009  108.42857 
♂  699-1  KO  4/30/2007  6/20/2009  111.71429 
♂  389-2  KO  3/6/2006  4/27/2008  111.85714 
♂  610-1  KO  1/22/2007  3/19/2009  112.42857 
♂  625-1  KO  2/20/2007  5/15/2009  116.42857 
♂  303-3  KO  12/12/2005  3/20/2008  118.42857 
♂  701-3  KO  4/30/2007  8/15/2009  119.71429 
♂  480-1-(w)  KO  7/9/2006  11/7/2008  121.71429 
♂  190-2  KO  9/28/2005  2/10/2008  123.57143 
♂  182-1  KO  9/23/2005  2/15/2008  125 
♂  191-3  KO  9/28/2005  2/23/2008  125.42857 
♂   J9-1  KO  1/20/2005  7/6/2007  128.14286 
♂  64-1  KO  2/22/2005  9/7/2007  132.42857 
♂  231-1  KO  9/28/2005  4/17/2008  133.14286 
♂  48-1  KO  3/3/2005  9/27/2007  134 
♂  503-1(w)  KO  8/21/2006  5/5/2009  141.14286 
♂  230-1(w)  KO  9/28/2005  6/17/2008  141.85714  TUMOR  Colon tumor 
♂  479-1(b)  KO  7/9/2006  4/19/2009  145 
♂  40-1  KO  3/28/2005  1/8/2008  145.14286 
♂  251-1  KO  11/16/2005  8/30/2008  145.42857  TUMOR  Chest wall tumor 
♂  J3-3  KO  1/10/2005  10/26/2007  145.57143  TUMOR 
Fast growing tumor 
 in the front right leg 
♂  65-2  KO  2/22/2005  12/16/2007  146.71429 
♂  181-1  KO  9/19/2005  7/31/2008  149.42857 
   




































































































♂  482-3(w)  KO  7/9/2006  5/23/2009  149.85714 
♂  167-2  KO  8/28/2005  7/13/2008  150 
♂  63-3  KO  2/21/2005  1/8/2008  150.14286 
♂  140-3  KO  7/12/2005  6/11/2008  152.14286 
♂  275-2  KO  11/22/2005  12/3/2008  158.14286 
♂  J33-2(alb)  KO  1/27/2005  2/9/2008  158.28571 
♂  43-4  KO  3/28/2005  5/13/2008  163.14286 







metabolites  (for  assignments  see  Nicholson  et  al.,  1995).  Positive
values over the baseline in this loading plot mean an increase in the
level of the metabolite parallel to an increase in the value of the







of  WT  n=43  and  RasGrf1
‐/‐  n=42  male  mice,  same  group  of
animals  as  in  Figure  1,  but  excluding  those  animals  that
presented tumours at the time of death (p<0.05).  
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  normal  0        
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SIGNATURE        
 
                     *Vital functions: afflicting one of the  5 senses and physiological functions (food ingestion, urinate,  
                    defecate and motility) 
                   0‐7: daily monitoring 
                   8‐13: seek advice with veterinarians and plan for treatment (first aid, analgesics, etc.) 
                  14‐17: seek advice with veterinarians and plan for euthanasia 
                 ≥ 18: immediate euthanasia 